2021
Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19 JACC State-of-the-Art Review
Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Dreyfus I, Kakavand H, Ariannejad H, Gupta A, Madhavan MV, Van Tassell BW, Jimenez D, Monreal M, Vaduganathan M, Fanikos J, Dixon DL, Piazza G, Parikh SA, Bhatt DL, Lip GYH, Stone GW, Krumholz HM, Libby P, Goldhaber SZ, Bikdeli B. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19 JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2021, 78: 1635-1654. PMID: 34649702, PMCID: PMC8504484, DOI: 10.1016/j.jacc.2021.08.021.Peer-Reviewed Original ResearchConceptsLipid-modulating agentsEndothelial activationLow high-density lipoprotein cholesterolCOVID-19High-density lipoprotein cholesterolLipid modulating agentsHigh triglyceride levelsMultiorgan manifestationsStatin trialsLipoprotein cholesterolSystemic inflammationTriglyceride levelsJACC StateWorse outcomesInflammatory responsePatient managementRCTsCoronavirus diseaseViral entrySystematic searchLipid raft disruptionTrialsPatientsRaft disruptionPrevention
2006
Renal Impairment and Outcomes in Heart Failure Systematic Review and Meta-Analysis
Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM. Renal Impairment and Outcomes in Heart Failure Systematic Review and Meta-Analysis. Journal Of The American College Of Cardiology 2006, 47: 1987-1996. PMID: 16697315, DOI: 10.1016/j.jacc.2005.11.084.Peer-Reviewed Original ResearchConceptsRenal impairmentHF patientsSevere impairmentRenal functionExcess mortalityMortality riskSystematic reviewAssociated mortality riskHeart failure patientsCause mortality riskPrecise risk estimatesCause mortalityFailure patientsDL increaseRisk stratificationTherapeutic strategiesPatientsMeta-AnalysisMortalityRisk estimatesImpairmentSystematic searchMin decreaseRiskCreatinine